All In Biotech

NDA 219683 · Janssen Biotech

Inlexzo

Gemcitabine Hydrochloride · Intravesical · Nucleoside Metabolic Inhibitor

Breakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 9, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,514

702 Phase 3, 512 recruiting

FAERS reports

484

108 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. INLEXZO is a nucleoside metabolic inhibitor-containing intravesical system, indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )

Mechanism: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 9, 2025 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyLabelLetterReview
1 products under this application
  • INLEXZO · GEMCITABINE HYDROCHLORIDE EQ 225MG BASE · SYSTEM, INTRAVESICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gemcitabine" as an intervention, any sponsor and status, largest first.

All 3,514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pollakiuria96
  • dysuria94
  • micturition urgency52
  • urinary tract infection45
  • bladder pain38
  • bladder spasm31
  • haematuria27
  • drug intolerance25
  • pain22
  • product dose omission issue19
  • lower urinary tract symptoms18
  • adverse event15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202526
2026458

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,445 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.